Viracta Therapeutics Inc (VIRX) concluded trading on Wednesday at a closing price of $0.19, with 4.09 million shares of worth about $0.78 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -61.31% during that period and on January 08, 2025 the price saw a loss of about -11.04%. Currently the company’s common shares owned by public are about 39.74M shares, out of which, 28.01M shares are available for trading.
Stock saw a price change of 16.66% in past 5 days and over the past one month there was a price change of 19.17%. Year-to-date (YTD), VIRX shares are showing a performance of 16.66% which decreased to -68.72% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.13 but also hit the highest price of $1.31 during that period. The average intraday trading volume for Viracta Therapeutics Inc shares is 2.70 million. The stock is currently trading -6.34% below its 20-day simple moving average (SMA20), while that difference is up 2.19% for SMA50 and it goes to -58.75% lower than SMA200.
Viracta Therapeutics Inc (NASDAQ: VIRX) currently have 39.74M outstanding shares and institutions hold larger chunk of about 13.00% of that.
The stock has a current market capitalization of $7.46M and its 3Y-monthly beta is at 0.69. It has posted earnings per share of -$1.10 in the same period. It has Quick Ratio of 0.76. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for VIRX, volatility over the week remained 21.11% while standing at 18.06% over the month.
Stock’s fiscal year EPS is expected to rise by 35.23% while it is estimated to increase by 35.09% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Leerink Partners on August 16, 2024 offering a Market perform rating for the stock and assigned a target price range of between $5 and $3 to it. Coverage by RBC Capital Mkts stated Viracta Therapeutics Inc (VIRX) stock as an Outperform in their note to investors on February 01, 2022, suggesting a price target of $10 for the stock. On May 03, 2021, H.C. Wainwright Initiated their recommendations, while on April 26, 2021, SVB Leerink Initiated their ratings for the stock with a price target of $18. Stock get an Outperform rating from Evercore ISI on March 25, 2021.
